396 articles with AmerisourceBergen
AmerisourceBergen Corporation announced that its Board of Directors has elected Redonda Miller, M.D., 56, as a new independent director, effective January 1, 2023.
AmerisourceBergen Corporation announced a secondary public offering of 10 million shares of common stock of the Company held by Walgreens Boots Alliance Holdings LLC.
AmerisourceBergen Corporation reported that in its fiscal year 2022 fourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.
9/28/2022A cloudy ophthalmic space got a little clearer Wednesday with the two collaborations by Visus Therapeutics and Outlook Therapeutics, now preparing for FDA approval.
AmerisourceBergen Announces Date and Time for Fourth Quarter Fiscal 2022 Earnings Release.
AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Lorence H. Kim, M.D., 48, as a new independent director, effective October 1, 2022.
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
Outlook Therapeutics, Inc. and AmerisourceBergen announced today that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved by the U.S. Food and Drug Administration (FDA).
AmerisourceBergen Corporation (NYSE: ABC) today announced that it has signed a definitive agreement to acquire PharmaLex Holding GmbH, a leading provider of specialized services for the life sciences industry, from funds advised by AUCTUS Capital Partners AG for €1.28 billion in cash, subject to certain customary adjustments.
AmerisourceBergen Hosts Inaugural Disparities in Cancer Care Summit.
AmerisourceBergen to Launch Digital Therapeutics Platform to Facilitate Access to Innovative Products
As the pipeline of digital therapeutics (DTx) continues to expand, AmerisourceBergen today announced plans to launch DTx Connect.
AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter of Fiscal 2022 on Wednesday, August 3, 2022, prior to the opening of trading on the New York Stock Exchange.
The AmerisourceBergen Foundation , an independent not-for-profit charitable giving organization focused on supporting health-related causes that enrich the global community, has committed $150,000 to the United Nations Foundation ’s Shot@Life campaign to support vaccine equity.
AmerisourceBergen Corporation hosted an investor day event in New York City. Steven H. Collis, Chairman, President & Chief Executive Officer; James F. Cleary, EVP & Chief Financial Officer; Bob Mauch, EVP & Group President; and Susan Lorenz-Fisher, SVP, Corporate Responsibility & Sustainability, discussed the company’s purpose, strategic imperatives, ESG commitments, and long-term financial growth outlook.
AmerisourceBergen Investor Day to Highlight Strategic Imperatives and Provide Long-Term Financial Outlook
AmerisourceBergen Corporation reiterated its previously provided guidance for fiscal year 2022 and announced that its Board of Directors has authorized a new share repurchase program.
AmerisourceBergen Launches Clinical Trial Navigator to Bolster Equitable and Accessible Community-Based Research Opportunities Nationwide
AmerisourceBergen Launches Clinical Trial Navigator to Bolster Equitable and Accessible Community-Based Research Opportunities Nationwide.
AmerisourceBergen Corporation (NYSE: ABC) today announced that it is resuming share repurchases with excess free cash flow in accordance with the company’s disciplined approach to capital allocation.
AmerisourceBergen Corporation reported that in its fiscal year 2022 second quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.
AmerisourceBergen & Biopharmaceutical Companies Discuss Strategies to Advance Pharmaceutical Innovation and Access at ThinkLive Commercialization Conference
AmerisourceBergen & Biopharmaceutical Companies Discuss Strategies to Advance Pharmaceutical Innovation and Access at ThinkLive Commercialization Conference.
AmerisourceBergen, a global healthcare company, announces a program designed to help hospitals and health systems launch or optimize home infusion service lines.
AmerisourceBergen Partners with Chronicled to Optimize Pharmaceutical Chargeback Accuracy Using Blockchain-Powered Technology
Global healthcare company AmerisourceBergen (AB) announced today its partnership with Chronicled , the administrator of the MediLedger Network, to leverage a new blockchain-powered solution designed to enhance pharmaceutical chargeback accuracy and significantly reduce chargeback rejections.